Insight

Tuomas Tammela: Co-targeting classical cells and KRAS augments response in pancreas cancer

Photo of Tuomas Tammela from X

Jul 10, 2024, 07:19

Tuomas Tammela: Co-targeting classical cells and KRAS augments response in pancreas cancer

Tuomas Tammela, Associate Member at Memorial Sloan Kettering Cancer Center, shared on X:

“New Paper! Anupriya Singh and Hannah Styers from the lab find acute resistance to targeting KRAS in pancreas cancer is surprisingly driven by a classical epithelial state.

Co-targeting classical cells and KRAS augments response – clinically important!”

Source: Tuomas Tammela/X

A classical epithelial state drives acute resistance to KRAS inhibition in pancreas

Authors: Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Stefan R. Torborg, Jung Yun Kim, Olivera Grbovic-Huezo, Huijin Feng, Zeynep Cagla. Tarcan, Hulya Sahin Ozkan, Jill Hallin, Olca Basturk, Rona Yaeger, James G. Christensen, Doron Betel, Yan Yan, Iok In Christine Chio, Elisa de Stanchina, Tuomas Tammela

Tuomas Tammela

Anupriya Singh Anupriya Singhal cancer Doron Betel Elisa de Stanchina Hannah C. Styers Hannah Styers Huijin Feng Hulya Sahin Ozkan Iok In Christine Chio James G. Christensen Jill Hallin Jonathan Rub Jung Yun Kim KRAS Memorial Sloan Kettering Cancer Center Olca Basturk Olivera Grbovic-Huezo OncoDaily Oncology Rona Yaeger Stefan R. Torborg Tuomas Tammela Yan Yan Zeynep Cagla. Tarcan Zhuxuan Li

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more